Evidence map›Paper›PMID 32542526›Full record

Observational studyJournal of neurology2020

Change over time in ability to perform activities of daily living in myotonic dystrophy type 1.

Erik Landfeldt, Nikoletta Nikolenko, Cecilia Jimenez-Moreno, Sarah Cumming, Darren G Monckton, Catharina G Faber, Ingemar S J Merkies, Grainne Gorman, Chris Turner, Hanns Lochmüller

Registry-linked trialOpen access · hybridAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Journal of neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05532813 (Evaluation of the Efficacy and Safety of Metformin in the Myotonic Dystrophy Type 1), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05532813 phase3recruitingnot on this mapstarted 2024, after this paper: background citation

Evaluation of the Efficacy and Safety of Metformin in the Myotonic Dystrophy Type 1 (Steinert's Disease). A Phase III, Prospective, Multicentre, Randomized, Double-blind Controlled Study

TypeinterventionalSponsorAssistance Publique - Hôpitaux de ParisRan2024 to 2026Enrolled142ConditionsSteinert's Disease, Myotonic Dystrophy 1, MetforminArmsTreatment taken
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Observational
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 6 countries.

Erik LandfeldtDepartment of Women's and Children's Health, Karolinska Institutet, Karolinska Vägen 37A, 171 76, Stockholm, Sweden. erik.landfeldt@ki.se.ORCID http://orcid.org/0000-0002-5758-7151
Nikoletta NikolenkoNational Hospital for Neurology and Neurosurgery, Queen Square, University College London Hospitals NHS Foundation Trust, London, UK.
Cecilia Jimenez-MorenoWelcome Center for Mitochondrial Research, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.
Sarah CummingInstitute of Molecular, Cell and Systems Biology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
Darren G MoncktonInstitute of Molecular, Cell and Systems Biology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
Catharina G FaberDepartment of Neurology, School of Mental Health and Neuroscience, Maastricht University Medical Center, Maastricht, The Netherlands.
Ingemar S J MerkiesDepartment of Neurology, School of Mental Health and Neuroscience, Maastricht University Medical Center, Maastricht, The Netherlands.
Grainne GormanInstitute of Neuroscience, Wellcome Trust Centre for Mitochondrial Research, University of Newcastle, Newcastle, UK.
Chris TurnerNational Hospital for Neurology and Neurosurgery, Queen Square, University College London Hospitals NHS Foundation Trust, London, UK.
Hanns LochmüllerDepartment of Neuropediatrics and Muscle Disorders, Medical Centre, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Maastricht University · NLUniversity College London Hospitals NHS Foundation Trust · GBUniversity of Glasgow · GBWellcome Centre for Mitochondrial Research · GBKarolinska Institutet · SEUniversity of Ottawa · CA

Funding

Medical Research Council G1002274
6 · The paper itself

Abstract

objectiveThe objective of this longitudinal, observational study was to investigate change over time in ability to perform activities of daily living in myotonic dystrophy type 1 (DM1).

methodsAdults with genetically confirmed DM1 were recruited as part of the PhenoDM1 study in the UK. Data on activities of daily living were recorded through the DM1-Activ

resultsOur sample comprised 150 patients with DM1 (mean age: 45 years; 52% female). Mean follow-up was 383 days. Mean DM1-Activ

conclusionsChange over time in ability to perform activities of daily living as recorded through the DM1-Activ

Indexed as

Activities of Daily LivingMyotonic DystrophyAdultFemaleHumansLongitudinal StudiesMaleMiddle AgedActivities of daily livingDisabilityParticipationPhenoDM1

Identifiers

PMID32542526
PMCPMC7578145
OpenAlexW3034687606

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.